Documente Academic
Documente Profesional
Documente Cultură
PLAMANUL
- oxigenare Hb - filtru (particule, bacterii) - eliminarea CO2 echilibru acido-bazic CIRCULATIA PULMONARA Sange venos a. pulmonara Capilare Vene pulmonare CIRCULATIA BRONSICA sange arterial a. bronsice Capilare Vene sistemice
CIRCULATIA BRONSICA
Sunt fiziologic dr-stg
(pana la 30% din DC) - bronsiectazii - fibroza chistica - boli congenitale cardio-vasculare
NORMAL A SISTEMICE media 20-25% din diam. vasului A. PULMONARE - media < 10- 5% din diam. vasului Arteriolele pulmonare nu au tunica medie si nu contribuie la rezistenta vasculara
VD fluxul coronarian cel mai mare in sistola - depinde de gradientul pres. pulm. aorta Pres. VD creste gradientul scade fluxul coronar drept scade ischemie VD
HIPOXIA VASOCONSTRICTIE PULMONARA -histamina receptori H1 vasculari - endoteliu - echilibru NO endoteline - patrunderea Ca 2+ in celula musculara neteda
HIPOXIA CRONICA 1. Extensia musculaturii netede in peretele arterelor din periferia plamanilor 2. Ingrosarea peretilor arterelor musculare 3. Reducerea nr. arterelor cresterea raportului alveole/artere
VASOCONSTRICTIE
Hipoxia Acidoza Prostaglandine F2 si A2 HISTAMINA H1 SEROTONINA ? ANGIOTENSINA A2 ALTITUDINE
VASODILATATIE
Alcaloza PROSTAGLANDINE I2 si E BLOCANTI STIMULARE (ISOPROTERENOL) ACETILCOLINA (prin EDRF) HISTAMINA (prin H2 ?) INDOMETACIN creste rezistenta
pulmonara
La 10 000 m altitudine
TA pulmonara medie = 25 mm Hg in repaus > 50 mm Hg in efort
CLASIFICAREA HTP
Dana Point, 2008
1. HTP arteriala 1.1. Idiopatica 1.2. Ereditara 1.3. Indusa de droguri si toxine 1.4. Asociata cu:
Boli de colagen HIV Hipertensiune portala Boli cardiace congenitale Schistosomiaza Anemie hemolitica cronica
1.5. HTP persistenta la nou nascut 1 Boala venoocluziva pulmonara si/sau hemangiomatoza capilara pulmonara
CLASIFICAREA HTP
Dana Point, 2008
2. HTP prin suferinta ventriculului stang 2.1. Disfunctie sistolica 2.2. Disfunctie diastolica 2.3. Boli valvulare
CLASIFICAREA HTP
Dana Point, 2008
3. HTP prin boli pulmonare sau hipoxie 3.1. BPOC 3.2. Boli interstitiale 3.3. Alte boli cu restrictie si obstructie 3.4. Apneea de somn 3.5. Boli cu hipoventilatie alveolara 3.6. Expunerea cronica la mare altitudine 3.7. Anomalii de dezvoltare fizica
CLASIFICAREA HTP
Dana Point, 2008
4. HTP prin tromboembolism 5. HTP prin factori multipli neclari 5.1. Boli hematologice: mieloproliferare, hipersplenism 5.2. Boli sistemice: sarcoidoza, histiocitoza pulmonara cu celule Langerhans 5.3. Boli metabolice: B. Gaucher, glicogenoze, disfunctii tiroidiene 5.4. Altele: obstructii tumorale, mediastinita fibrozanta,, IRC sau dializa
Variabilitatea reactivitatii vasculare pulmonare: creste presiunea venoasa distrugere sau inchidere de cai aeriene hipoxie creste presiunea in a. pulmonara creste presiunea venoasa edem interstitial rigidizarea vaselor HTP drenajul limfatic creste starea VD
normal hipertrofic insuficient miopatic (+ VS) hipoperfuzat (infarct)
Volumul sanguin pulmonar (depinde de debitul celor 2 ventriculi si de distensibilitatea vaselor pulmonare)
MODIFICARI ANATOMICE
Celule endoteliale capilare umflate Membrane bazale capilare ingrosate Edem interstitial Rupturi de membrane bazale transudare de eritrocite hemosideroza Alveole fibroase Destindere de limfatice
TABLE 73-2 -- Clues for Interpretation of Diagnostic Tests for Pulmonary Hypertension
Test Chest x-ray Notable Findings Enlargement of central pulmonary arteries reflects level of PA pressure and duration. Right axis deviation and precordial T wave abnormalities are early signs. Elevated pulmonary artery pressure causes restrictive physiology. Nonsegmental perfusion abnormalities can occur from severe pulmonary vascular disease. Minor interstitial changes may reflect diffuse disease; mosaic perfusion pattern indicates thromboembolism and/or left heart failure.
Echocardiography
Right ventricular enlargement will parallel the severity of the pulmonary hypertension. Minor right to left shunting rarely produces hypoxemia. This is too unreliable for following serial measurements to monitor therapy. This is very helpful to assess the efficacy of therapy. Severe exerciseinduced hypoxemia should cause consideration of a right-to-left shunt.
Exercise testing
SINDROM EISENMENGER
Toate sunturile sistemico-pulmonare rezultand din mari defecte care duc la cresteri de presiune in VD si la inversarea suntului (pulmonar-sistemic) sau sunt bidirectional cu: cianoza, eritrocitoza si multiple suferinte de organ
MODIFICARI ANATOMICE
GR. I : hipertrofia mediei artereor mici musculare GR. II : + proliferarea intimei GR. III: + fibroza concentrica cu obliterare de vase GR. IV: leziuni plexiforme, dilatatii, trombi GR. V: complexe plexiforme, leziuni angiomatoase si cavernoase si hialinizaea fbrozei intimale GR. VI: arterita necrozanta
Histopathology of endothelial cell lesions in IPAH. A. Pulmonary artery showing medial hypertrophy and lined by a single layer of endothelial cells, as outlined by Factor VIII related antigen immunostaining (arrow). Plexiform lesion (outlined by the rim of arrowheads) with the proximal vascular arterial segment with marked intimal and medial thickening by smooth muscle cells (arrow). Note the proliferation of endothelial cells with the outer edge (35 oclock) occupied by dilated blood vessel-like structures. C. Cross section of a plexiform lesion, outlined by arrowheads. Note perilesional inflammatory infiltrate (arrow). D. High magnification histology of plexiform lesions shown slit-like vascular channels lined by hyperchromatic and cuboidal endothelial cells. Cells in the core do not display distinct cytoplamic borders. E. Low magnification immunohistology with Factor VIII related antigen immunohistochemistry of different endothelial cell based vascular lesions. This area has revascularized lesions (possibly an organized thrombus), with well-formed and distinct small capillaries/vessels (arrowhead), a plexiform lesion (arrow), and dilated/angiomatoid lesions (between arrowheads). F. High magnification immunohistology of cellular plexiform lesion stained with Factor VIII related antigen (arrowheads). G and H. Histological identification of plexiform and dilation lesions (G) is markedly improved by Factor VIII related antigen immunohistochemistry (H) (arrowheads), while the parent vessel (arrow) shows mild medial remodeling. I. Highlight of vascular dilation/angiomatoid lesions with Factor VIII related antigen immunohistochemistry. J. Endothelial cells in plexiform lesion is highlighted by CD34 immunohisochemistry (arrowheads). Proximal pulmonary artery with marked intima and medial thickening is highlighted by the arrow. K and I. Endothelial cells are highlighted by CD31 immunohistochemistyr (arrowheads). Note that capillary endothelial cells express CD31 as well (arrow in I),
A. Fibrotic, relatively paucicellular intima thickening (outlined by arrowheads) in a pulmonary artery with the media highlighted with the arrow. B. Marked intima remodeling with almost complete obliteration by fibrous tissue with a marked intravascular and perivascular inflammatory infiltrate (arrows). C. Smooth muscle cell hypertrophy, with prominent thickening of medial layer (arrow). D. Highlight of medial hypertrophy with smooth muscle actin immunohistochemistry. E. Markedly remodeled pulmonary artery with endothelial cell layer highlighted by Factor VIII related antigen immunohistochemistry. Note that the intima and medial smooth muscle cells are negative for Factor VIII related antigen reactivity. F. Ingrowth of smooth muscle cells in a plexiform lesions, highlighted by smooth muscle cell actin immunohistochemistry (arrow).
Veno-occlusive PH. A. Low-power histological view of thickened pulmonary veins running into the lung parenchyma from the pleural surface (left edge) (arrows). Note marked vein wall thickening and decreased lumen. Adjacent alveoli are filled with blood and show septal thickening with engorged capillaries (arrowhead). B. Marked vein thickening with intimal projection probably representing organized thrombus (arrow). Alveolar hemorrhage and septal thickening are highlighted with arrowhead. C and D. Movat stained pulmonary vein showing arterialization pattern with internal and external elastic layers (arrow). The vein shows marked intima thickening with organized thrombus (arrowheads).
Rx n HTP
Normal
Flux crescut in lobii inferiori Gravitatie Presiuni diferite intra alveolare Raport A/B = 1,2 : 1
Rx n HTP
HTP arteriala - vasoconstrictie periferica - vasospasm - ingrosarea peretelui vascular
Rx
- scade circulatia (creste transparenta) in 1/3 ext. - vasele centrale elastice se largesc - calcificari ale vaselor centrale
Rx n HTP
P venoasa > 8 12 mm Hg fluxul pulmonar este redistribuit spre lobii superiori Rx inversare a aspectului normal (cefalizarea fluxului arterial si venos) P venoasa > 25 mm Hg
Edem pulmonar
Mecanisme
Rx n HTP
Sechestrarea de lichid interstitial in lobii inferiori Presiunea interstitiala Complianta pulmonara Fluxul spre lobii inferiori + Spasm arterial
HTP IDIOPATICA
ETIOLOGIE
Embolism pulmonar recurent, asimptomatic Embolism amniotic Tromboza in situ, tulburari de coagulare si fibrinoliza , contraceptive Vasoconstrictie cronica necroza fibrinoida leziuni plexiforme Vasculita generala cu fenomen Raynaud Hipersensibilitate la droguri Ingestia de fumarat de aminorex (anorexigen) Hormoni feminini
HTP IDIOPATICA
MODIFICARI HISTOLOGICE
Ingrosarea intimala a a. mici si arteriole cu fibroza in foi de ceapa Ingrosarea mediei a. musculare si muscularizarea arteriolelor Arterita necrozanta cu necroza fibrinoida Leziuni plexiforme arteriopatie pulmonara plexogenica umbre vasculare reducerea patului vascular
HTP IDIOPATICA
HIPOXIE raspuns anormal disfunctie endoteliala
Tromboza
Vasoconstrictie necroza fibrinoida
Leziuni plexiforme
MOARTEA
DUREREA TORACICA
HTP IDIOPATICA
SEMNE CLINICE Zgomot II intarit la pulmonara Suflu sistolic la pulmonara Semne de insuficienta cardiaca dreapta Semne de regurgitare triscuspidiana Cianoza - tardiv prin deschidere de foramen ovale Paralizie de recurent (rara)
LABORATOR
HTP IDIOPATICA
- Uneori defecte de coagulare si fibrinoliza - Disfunctie restrictiva
ECHOCARDIOGRAFIA Marirea atriului si ventriculului drept Cavitati stangi normale Ingrosarea septului Regurgitare tricuspidiana si prolaps de valva mitrala secundare dilatatiei de VD
HTP IDIOPATICA
SCINTIGRAFIA PULMONARA - normala
In stadii avansate poate fi daunatoare trasorul legat de albumina procoagulant
BIOPSIA PULMONARA
HTP IDIOPATICA
DIAGNOSTIC DIFERENTIAL
HTP secundara (mai benigna si mai tratabila)
TESTUL VASODILATATOR
In sala de cateterism cardiac PAPm dupa administrarea de NO inhalator (sau adenozina iv, epoprostenol iv sau inhalator) Test + = reducerea cu 20% a PAPm sau a rezistentei vasculare pulmonare bolnavul va primi vasodilatator indelungat
PROGNOSTICUL
Supravietuirea medie in HTP netratat = 2,8 ani Factori de prognostic: Varsta < 14 ani sau 65 ani prognostic prost Clasa NYHA: I II: supravietuire 6 ani in medie III: supravietuire 2,5 ani in medie IV: supravietuire 0,5 ani in medie Scaderea capacitatii de efort Sincopa Hemoptizie Semne de insuficienta ventriculara dreapta O2 in a pulmonara > 63 55% supravietuire la 5 ani < 63 17% supravietuire la 5 ani Indexul cardiac < 2,1 l/min/m2 supravietuire medie 17 luni Presiunea in AD < 10 mmHg - supravietuire 4 ani in medie > 20 mmHg - supravietuire medie o luna Test de vasodilatatie negativ
2. Oxigenoterapia
Se recomanda monitorizarea Sat O2 nocturna, Sat O2 < 90% in aerul atmosferic corectabila la administrarea de O2, indica oxigenoterapia nocturna
TRATAMENTUL MEDICAL
4. Tratamentul vasodilatator
Antagonistii de Ca (diltiazem sau nifedipina):
HTP de tip arterial cu test vasodilatator pozitiv CI in : HTP venoasa (precipita EPA) HTP hipoxica din bolile cronice pulmonare cu Sat O2 in sangele venos < 63% (agraveaza hipoxemia) PAD > 10 mm Hg Index cardiac < 2,1 l/min/m2
Responders: Ca.-blockers
Begin low dosage , increase weekly Less than of pts tolerate maximum dosage
TRATAMENTUL MEDICAL
Indicatii Bolnavii cu ICC cl III IV, index cardiac < 2,1 l/min/m2 si/sau Sat O2 in artera pulmonara < 63% si/sau PAD > 10 mmHg, indiferent de testul vasodilatator Toti bolnavii care nu raspund la tratamentul medical conventional, in asteptarea transplantului pulmonar
Prostanoid analogues
Epoprostenol
short HL, temp.-dependent , i- v (infusion pump ) , local facilities 2-4ng/kg/min ..20-40 ( tolerance , rebound , adverse reactions: common) >100.000 $ /year
3 month results: indic. surv/altern
Rubin LJ Ann. Intern.Med. 1990;112:485-92 Conversion to oral agents ?? Barst RJ N.Engl. J Med 1996;334:296-304 Badesch DB Ann. Intern.Med. 2000;132:425-34
Treprostenil
sufficient chemical stability to be administered at ambient temperature allow iv / subcutaneous /oral ( bid ) and inhalatory adm.(6-9 d )
Beraprost
Orally :40-80microg qid/zi efficacy does not appear to be sustained with extended duration of therapy
J Am CollCardiol. 2003 Jun 18;41(12): 211925
Iloprost
Inhalations 6-12 times/d (20-40 microg/d.)
Advant: selective to pulm.circ.
Type B receptor (endotelial): increases the synthesis of nitric oxide ( vasodilation ) Type B receptor (SMC): activates aldosterone, thromboxane, norepinephrine. ( vasoconstriction )
125 mg bid
10% liver enzimes >
Ambrisentan ARIES-2 . Am J Respir Cirt Care Med. 2006;173: lower incidence of liver enzyme abnormality Ann. Pharmacother, 2008; 42(11): 1653 absence of significant drug interactions 2004 : Level of evidence : C
Phosphodiesterase inhibitors
Sildenafil ( REVATIO )
2008 Apr
Tadalafil ( Cialis )
longer half-life (17.50 hours ) marketing approval began in late 2008 J Am Coll Cardiol, 2004; 44:1488-1496 Circulation. 2004;110:3149-3155
not
kinetics of pulmonary vasorelaxation (most rapid effect by vardenafil) selectivity for the pulmonary circulation (sildenafil and tadalafil, but
TRATAMENTE CHIRURGICALE
Septostomie atriala. Procedeu paleativ ce scade presiunea
in inima dreapta. Indicatii:
HTP severa, care nu raspunde la prostaglandine Se exclud pacientii cu Insuf Ventr dr severa, disfunctie de VS sau in stare critica
TRATAMENTE CHIRURGICALE
Indicatii HTPP simptomatica, progresiva in ciuda tratamentului medical optim, cu test de mers de 6 min < 400 m, cu index cardiac < 2,1 l/min/m2 si/sau Sat O2 in artera pulmonara < 63% si/sau PAD > 10 mm Hg sau PAP m > 55 mmHg
begin pharmacological treatment in sec. PHT ? Adapted to etiology ! Unknown borderline ! Is it harmful to use CCB in nonresponders ? Yes , at least for high doses
ACCP Gd.: Level of evidence: expert opinion; benefit: substantial; grade of recommendation: E/A.
Would it be better to use the more active drugs for responders also ? Probably yes , but economically unwise
How useful is multiple drug therapy Which order of introduction /doses ? BREATHE -2